02409nas a2200541   4500000000100000008004100001260001300042653001200055653002300067653001800090653002300108653001800131653001400149653002000163653002900183653002200212653002100234653001600255653001400271653000900285653000900294653000900303653002400312653002500336653001900361653001700380653002100397653002700418653002200445653004800467653001100515653001800526100001600544700001600560700001500576700002000591700001700611700001700628700001700645700001700662700001400679700001400693245008900707300001100796490000600807520104000813022001401853       2013                            d  c2013 Feb10aAnimals10aBacterial Proteins10aBiotechnology10aCell Proliferation10aChaperonin 6010aCytokines10aFungal Vaccines10aGene Transfer Techniques10aImmunity, Humoral10aImmunoglobulin G10aLactic Acid10aLiposomes10aLung10aMale10aMice10aMice, Inbred BALB C10aMycobacterium leprae10aNanotechnology10aNitric Oxide10aParacoccidioides10aParacoccidioidomycosis10aPolyglycolic Acid10aPolylactic Acid-Polyglycolic Acid Copolymer10aSpleen10aVaccines, DNA1 aRibeiro A M1 aSouza A C O1 aAmaral A C1 aVasconcelos N M1 aJeronimo M S1 aCarneiro F P1 aFaccioli L H1 aFelipe M S S1 aSilva C L1 aBocca A L00aNanobiotechnological approaches to delivery of DNA vaccine against fungal infection.  a221-300 v93 a<p>Vaccines play an essential role in keeping humans healthy. Innovative approaches to their use include the utilization of plasmid DNA encoding sequences to express foreign antigens. DNAhsp65 from Mycobacterium leprae is suitable for this purpose due to its ability to elicit a powerful immune response. Controlled release systems represent a promising approach to delivering vaccines. In this work, we used liposomes or PLGA systems to deliver DNAhsp65 to treat the pulmonary fungal infection Paracoccidioidomycosis. Both formulations modulated a protective immune response and reduced the pulmonary fungal burden even in the groups receiving less than four times the amount of the DNAhps65 entrapped within the nanoparticles. Although both systems had the same effective therapeutic results, the advantage of the liposome formulation was that it was administered intranasally, which may be more easily accepted by patients. These systems are a great alternative to be considered as adjuvant vaccine therapy for systemic mycosis.</p>  a1550-7033